Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Stock Down 0.5 %
NASDAQ:FENC traded down $0.04 during trading hours on Thursday, reaching $7.05. 44,666 shares of the company were exchanged, compared to its average volume of 38,369. The company has a debt-to-equity ratio of 0.36, a quick ratio of 8.96 and a current ratio of 8.96. The stock's 50-day moving average is $6.17 and its 200-day moving average is $5.74. Fennec Pharmaceuticals has a twelve month low of $3.37 and a twelve month high of $7.59.
Fennec Pharmaceuticals (NASDAQ:FENC - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Research analysts expect that Fennec Pharmaceuticals will post -0.45 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts recently issued reports on FENC shares. Craig Hallum reissued a "buy" rating and set a $14.00 price target on shares of Fennec Pharmaceuticals in a report on Monday. Wedbush restated an "outperform" rating on shares of Fennec Pharmaceuticals in a research report on Wednesday, April 27th.